Bromocriptine in Central Hyperthermia after Severe Traumatic Brain Injury
| Autor: | Tamer Zakhary, Ahmed Sabry |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Hyperthermia
030506 rehabilitation medicine.medical_specialty Neurology Traumatic brain injury business.industry medicine.disease Bromocriptine 03 medical and health sciences 0302 clinical medicine Primary outcome Anesthesia medicine In patient Antipyretic 0305 other medical science business Feeding tube 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Open Journal of Emergency Medicine. :102-109 |
| ISSN: | 2332-1814 2332-1806 |
| DOI: | 10.4236/ojem.2017.53010 |
| Popis: | Strong evidence showed that fever after traumatic brain injury TBI is associated with increased mortality. In this study, we tried to evaluate the role of Bromocriptine in central hyperthermia in patients with severe TBI. This prospective controlled study was conducted on 50 severe TBI patients who admitted to the critical care department and confirmed on Computed Tomography (CT) of the brain and GCS of less than 9 at admission. Then, they were randomly assigned into 2 groups. Bromocriptine group (25) received bromocriptine 7.5 mg/day during 24 hours from admission through a naso-gastric (NG) feeding tube. Control group (25) received conventional treatment only. Temperature was measured every 2 hours. The antipyretic measures used were the same across all patients enrolled. The primary outcome was number of patients diagnosed with central hyperthermia. After the discharge of all patients, there was a statistically significant difference between the 2 groups in number of patients diagnosed with central hyperthermia (6 (24%) in bromocriptine group Vs 18 (72%) in control, p = 0.002). There were no differences in hospital length of stay (p = 0.904) or mortality (p = 0.393). Early administration of bromocriptine in severe TBI may be associated with lower incidence of central hyperthermia with no effect on length of stay or mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|